SCHEMBL23217627

SCHEMBL23217627

CCOC(=O)Cc1ccccc1OCc1cc(-c2csc(C(C)N)n2)c2occc2c1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CFD P00746 14/20 0.60
F11 P03951 3/20 0.38
TPSB2 P20231 3/20 0.38
BAX Q07812 1/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.36
TBXAS1 P24557 1/20 0.35
PKM P14618 1/20 0.35
MEN1 O00255 1/20 0.33
GALR3 O60755 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30010280 1.00 CFD (0.60) CFDF11TPSB2BAXALDH1A1
SCHEMBL29672986 0.90 CFD (0.73) CFDF11TPSB2
SCHEMBL29672981 0.90 CFD (0.73) CFDF11TPSB2
SCHEMBL23217512 0.90 CFD (0.73) CFDF11TPSB2
SCHEMBL30010615 0.87 CFD (0.55) CFDF11TPSB2BAXALDH1A1
SCHEMBL23217449 0.87 CFD (0.55) CFDF11TPSB2BAXALDH1A1
SCHEMBL23217192 0.86 CFD (0.53) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL23217613 0.86 CFD (0.53) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL29672942 0.86 CFD (0.53) CFDBAXALDH1A1MAPTTBXAS1
SCHEMBL30010424 0.86 CFD (0.53) CFDBAXALDH1A1MAPTTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed